Why aren't doctors using digital therapeutics?

Guest Blogger|29th November 2019

Image credit: Designed by pressfoto / Freepik (freepik.com)

In the digital age, the technology exists to better capture, analyse and share healthcare data to drive better patient outcomes, to improve their quality of life and ultimately to analyse aggregated, anonymised data to enhance our understanding of disease and population level outcomes.

With more than 300,000 healthcare apps available on the market today, it’s clear there is an abundance of healthcare technology available to meet a variety of patient, caregiver, and healthcare professional (HCP) needs. However, although HCPs are often initially excited about the digital therapeutics flooding the market, the uptake of these technologies is low.

This is not due to economic issues plaguing our healthcare systems. Recent analysis from IQVIA Institute for Human Data Science suggests that the use of digital health apps in five chronic disease patient populations could save the UK healthcare system an estimated £170 million per year. Despite these benefits, the National Health Service (NHS) has only just rolled out a 10-year, long-term plan to support a digitally enabled therapy assessment programme.

Across the Atlantic, the United States Food and Drug Administration (FDA) is also currently still in the pilot stage of its Software Precertification Program, which is redefining how the FDA regulates digital health devices. Although the consumer sector is using technology to solve customers’ challenges and enhance their experience, healthcare has fallen behind. This is in part due to the complexity of the healthcare industry, coupled with the high and sometimes fatal risks of failing to achieve the outcomes promised.

With 24 years of experience as a research and design professional, Stewart Anderson, Blue Latitude Health’s Senior User Experience Consultant, has honed his skills in digital service design, developing solutions that meet HCP and patient needs at the point of need. Here, he explains why doctors fail to prescribe digital health tools and how pharma companies can help to solve these challenges.

Delivering impactful customer engagements in COVID-19

Blue Latitude Health|14th July 2020

Blue Latitude Health, and our parent company Fishawack Health, have developed exclusive intellectual property, processes and tools to ensure you’re engaging customers in the right way. View our service one-pagers below to find out how we can help solve your challenges whether you’re in a medical, brand, portfolio or an above brand role.

read more

Top 5 tips for a multi-indication product launch

Sana Rahim|8th July 2020

Senior Associate Consultant Sana Rahim and Senior Consultant Victoria Clark explain the lessons the team has learned from launching six different indications of an oncology product in an accelerated timeframe.

read more

If our patients are diverse, why are clinical trials so white?

Ling Song|22nd June 2020

Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue and calls for the pharmaceutical industry to change its approach.

read more